**Table S2.** Characteristics of Individual Case Safety Reports (ICSRs) for non-pregnant women with psoriasis, stratified by each anti-TNF drugs.

| | **Anti-TNF drugs** | | | | |
|---|---|---|---|---|---|
| | **Adalimumab** | **Certolizumab** | **Etanercept** | **Golimumab** | **Infliximab** |
| **N. of ICSRs** | 4,493 | 803 | 4,614 | 269 | 1,602 |
| **Age range (%)** | | | | | |
| 0-1 Month | 0 (0.0) | 2 (0.2) | 2 (<0.1) | 0 (0.0) | 0 (0.0) |
| 2 Months - 2 Years | 0 (0.0) | 0 (0.0) | 1 (< 0.1) | 0 (0.0) | 0 (0.0) |
| 3-11 Years | 21 (0.5) | 0 (0.0) | 17 (0.4) | 2 (0.7) | 2 (0.1) |
| 12-17 Years | 33 (0.7) | 0 (0.0) | 51 (1.1) | 0 (0.0) | 7 (0.4) |
| 18-64 Years | 2,830 (63.0) | 503 (62.6) | 3,050 (66.1) | 174 (64.7) | 1,124 (70.2) |
| 65-85 Years | 652 (14.5) | 44 (5.5) | 974 (21.1) | 10 (3.7) | 209 (13.0) |
| More than 85 Years | 11 (0.2) | 1 (0.1) | 31 (0.7) | 0 (0.0) | 5 (0.3) |
| Not Specified | 946 (21.1) | 253 (31.5) | 488 (10.6) | 83 (30.9) | 255 (15.9) |
| **Type of report = Spontaneous (%)** | 4,493 (100.0) | 803 (100.0) | 4,614 (100.0) | 269 (100.0) | 1,602 (100.0) |
| **Source qualification (%)** | | | | | |
| Healthcare Professional | 3,608 (80.3) | 620 (77.2) | 2,481 (53.8) | 230 (85.5) | 1,404 (87.6) |
| Non-Healthcare Professional | 884 (19.7) | 183 (22.8) | 2,133 (46.2) | 39 (14.5) | 198 (12.4) |
| Not Specified | 1 (< 0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |